Thomsen GM, Gowing G, Svendsen S, et al. (2014) The past, present and future of stem cell clinical trials for ALS. Exp Neurol 262 Pt B: 127-137.Thomsen GM, Gowing G, Svendsen S, et al. The past, present and future of stem cell clinical trials for ALS. Exp Neurol, 2014, 262 ...
The paper said that human neural stem cell (hNSC) lines were injected into gray matter tracts of the lumbar or cervical spinal cord of 18 patients. For up to 60 months after surgery, none of the patients manifested severe adverse effects or increased disease progression because of the ...
We also review early clinical trials using these diverse types of stem cells. Advances in stem cell therapy are moving forward at breakneck pace, and if approached with attention to methodology and regulation, have the potential to significantly improve the care of patients with ALS. 展开 ...
The future success of cell replacement therapies for PD will depend on the ability to select the appropriate mDA cell lineage. Amyotrophic lateral sclerosis ALS, also known as Lou Gehrig's disease, is a neuro-degenerative disease affecting the spinal cord and brain stem and typically is adult-...
Stem cell technology is at an early stage but the desperate need for a therapy in ALS patients may legitimize clinical trials in absence of conclusive scientific evidence. This paper discusses the premises for stem cell therapy in ALS. 展开 ...
Although stem cell therapy shows potential as a disease-modifying treatment for AD, additional research is required to tackle the obstacles and enhance the therapeutic strategy. Thorough preclinical investigations and well-planned clinical trials are necessary to determine stem cell treatments' safety, eff...
An experimental stem cell therapy for the treatment of mild to moderateamyotrophic lateral sclerosis(ALS) received a resounding rejection today from a US Food and Drug Administration (FDA) advisory panel that cited efficacy, safety, and product manufacturing concerns. ...
The development of curative therapies for genetically complex diseases such as ALS has been delayed by thelack of relevant disease models. Recent advances using induced-pluripotent-stem-cell-derived motoneurons from patients harboring distinct ALS mutations have recapitulated essential disease features and ...
The past, present and future of stem cell clinical trials for ALS. Exp Neurol. 2014;262(pt B):127-137.PubMedGoogle ScholarCrossref 22. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised ...
Recently, human umbilical cord mesenchymal stem cell-derived conditioned medium (UC-CM) has been introduced to treat ALS patients. However, there is no research for the protective effect of UC-CM on the TDP-43 model of ALS. In this study, we evaluated the potential neuroprotective effect of ...